Edesa Biotech Stock Performance
| EDSA Stock | USD 1.17 0.06 4.88% |
The firm shows a Beta (market volatility) of 0.32, which means possible diversification benefits within a given portfolio. As returns on the market increase, Edesa Biotech's returns are expected to increase less than the market. However, during the bear market, the loss of holding Edesa Biotech is expected to be smaller as well. At this point, Edesa Biotech has a negative expected return of -0.57%. Please make sure to confirm Edesa Biotech's skewness, day typical price, and the relationship between the maximum drawdown and daily balance of power , to decide if Edesa Biotech performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Edesa Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in March 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Last Split Factor 1:7 | Dividend Date 2019-06-10 | Last Split Date 2023-10-11 |
1 | 12 Health Care Stocks Moving In Tuesdays Pre-Market Session | 11/04/2025 |
2 | Is Edesa Biotech Inc. stock affected by interest rate hikes - Market Trend Report Weekly Top Stock Performers List - newser.com | 11/07/2025 |
3 | Best data tools to analyze Edesa Biotech Inc. stock - 2025 Bull vs Bear Consistent Return Investment Signals - newser.com | 11/12/2025 |
4 | Edesa Biotech Inc. Stock Price Live Quotes Charts NASDAQ - StocksToTrade | 11/21/2025 |
5 | Acquisition by Nijhawan Pardeep of 8766 shares of Edesa Biotech subject to Rule 16b-3 | 12/01/2025 |
6 | Edesa Biotech, Inc. Short Interest Down 31.8 percent in December | 12/29/2025 |
7 | Acquisition by Nijhawan Pardeep of 10444 shares of Edesa Biotech subject to Rule 16b-3 | 01/05/2026 |
8 | Why Edesa Biotech Inc. stock could be next big winner - Daily Trainer Picks quick comparison of popular models - ulpravda.ru | 01/09/2026 |
9 | Acquisition by Olson Charles V of 20000 shares of Edesa Biotech at 0.8277 subject to Rule 16b-3 | 01/16/2026 |
10 | Acquisition by Nijhawan Pardeep of 5981 shares of Edesa Biotech subject to Rule 16b-3 | 01/29/2026 |
Edesa Biotech Relative Risk vs. Return Landscape
If you would invest 174.00 in Edesa Biotech on November 2, 2025 and sell it today you would lose (57.00) from holding Edesa Biotech or give up 32.76% of portfolio value over 90 days. Edesa Biotech is currently does not generate positive expected returns and assumes 3.643% risk (volatility on return distribution) over the 90 days horizon. In different words, 32% of stocks are less volatile than Edesa, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Edesa Biotech Target Price Odds to finish over Current Price
The tendency of Edesa Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 1.17 | 90 days | 1.17 | about 98.0 |
Based on a normal probability distribution, the odds of Edesa Biotech to move above the current price in 90 days from now is about 98.0 (This Edesa Biotech probability density function shows the probability of Edesa Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Edesa Biotech has a beta of 0.32 suggesting as returns on the market go up, Edesa Biotech average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Edesa Biotech will be expected to be much smaller as well. Additionally Edesa Biotech has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Edesa Biotech Price Density |
| Price |
Predictive Modules for Edesa Biotech
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Edesa Biotech. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Edesa Biotech's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Edesa Biotech Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Edesa Biotech is not an exception. The market had few large corrections towards the Edesa Biotech's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Edesa Biotech, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Edesa Biotech within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -1.14 | |
β | Beta against Dow Jones | 0.32 | |
σ | Overall volatility | 0.22 | |
Ir | Information ratio | -0.27 |
Edesa Biotech Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Edesa Biotech for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Edesa Biotech can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Edesa Biotech generated a negative expected return over the last 90 days | |
| Edesa Biotech may become a speculative penny stock | |
| Edesa Biotech has high historical volatility and very poor performance | |
| Edesa Biotech has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (7.19 M) with profit before overhead, payroll, taxes, and interest of 311.2 K. | |
| Edesa Biotech currently holds about 12.81 M in cash with (7.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.83. | |
| Roughly 17.0% of the company shares are held by company insiders | |
| Latest headline from prnewswire.com: Vaximm, an OSR Company, Receives Binding Term Sheet from BCM Europe for Global Exclusive License of VXM01 with 30M Upfront and Up to 815M in Milestones |
Edesa Biotech Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Edesa Stock often depends not only on the future outlook of the current and potential Edesa Biotech's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Edesa Biotech's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 5.7 M | |
| Cash And Short Term Investments | 10.8 M |
Edesa Biotech Fundamentals Growth
Edesa Stock prices reflect investors' perceptions of the future prospects and financial health of Edesa Biotech, and Edesa Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Edesa Stock performance.
| Return On Equity | -1.0 | ||||
| Return On Asset | -0.57 | ||||
| Current Valuation | 9.23 M | ||||
| Shares Outstanding | 8.33 M | ||||
| Price To Earning | (3.96) X | ||||
| Price To Book | 3.21 X | ||||
| Price To Sales | 120,478 X | ||||
| Gross Profit | 311.2 K | ||||
| EBITDA | (7.07 M) | ||||
| Net Income | (7.19 M) | ||||
| Cash And Equivalents | 12.81 M | ||||
| Cash Per Share | 0.83 X | ||||
| Total Debt | 1.21 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 2.68 X | ||||
| Book Value Per Share | 0.45 X | ||||
| Cash Flow From Operations | (7.32 M) | ||||
| Earnings Per Share | (1.21) X | ||||
| Market Capitalization | 9.75 M | ||||
| Total Asset | 13.53 M | ||||
| Retained Earnings | (65.91 M) | ||||
| Working Capital | 10.43 M | ||||
| Current Asset | 6.92 M | ||||
| Current Liabilities | 581.49 K | ||||
About Edesa Biotech Performance
By analyzing Edesa Biotech's fundamental ratios, stakeholders can gain valuable insights into Edesa Biotech's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Edesa Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Edesa Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 45.16 | 47.42 | |
| Return On Tangible Assets | (0.58) | (0.61) | |
| Return On Capital Employed | (0.44) | (0.46) | |
| Return On Assets | (0.58) | (0.61) | |
| Return On Equity | (1.10) | (1.15) |
Things to note about Edesa Biotech performance evaluation
Checking the ongoing alerts about Edesa Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Edesa Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Edesa Biotech generated a negative expected return over the last 90 days | |
| Edesa Biotech may become a speculative penny stock | |
| Edesa Biotech has high historical volatility and very poor performance | |
| Edesa Biotech has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (7.19 M) with profit before overhead, payroll, taxes, and interest of 311.2 K. | |
| Edesa Biotech currently holds about 12.81 M in cash with (7.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.83. | |
| Roughly 17.0% of the company shares are held by company insiders | |
| Latest headline from prnewswire.com: Vaximm, an OSR Company, Receives Binding Term Sheet from BCM Europe for Global Exclusive License of VXM01 with 30M Upfront and Up to 815M in Milestones |
- Analyzing Edesa Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Edesa Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Edesa Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Edesa Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Edesa Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Edesa Biotech's stock. These opinions can provide insight into Edesa Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Edesa Stock analysis
When running Edesa Biotech's price analysis, check to measure Edesa Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edesa Biotech is operating at the current time. Most of Edesa Biotech's value examination focuses on studying past and present price action to predict the probability of Edesa Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edesa Biotech's price. Additionally, you may evaluate how the addition of Edesa Biotech to your portfolios can decrease your overall portfolio volatility.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |